11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Jan
ZEAL
Baron, goodw..., alpe m.fl. kan i ikke tilføje hinanden på jeres messenger, snap el.lign. og føre je..
42
16 Jan
COLUM
Debatten her på EI handler om aktier og børsnoterede selskaber.   Da jeg regner med, at langt størst..
28
20 Jan
OMXC20
Min gode ven Viggo, der altid hjalp mig med forårsarbejdet var desværre kommet i fængsel. jeg skrev ..
20
18 Jan
OMXC20
  Serviceoplysning - valuation af novozymes i slutningen af indlægget. Lad mig starte med en meget v..
20
21 Jan
 
Alle kan ha en gevinst, nogle gange endda en kæmpegevinst på få dage. Men hvis du tror det er så let..
18
21 Jan
 
Først og fremmest skal du lære at stave til gevinst. Herefter skal du sætte dig grundigt ind i hvad ..
15
17 Jan
FING-B
Her er et eksempel der viser at man bør tænke over hvem man lytter på samt hvad man lægger op. Husk ..
15
20 Jan
TRYG
Til alle investorer, som vil lære noget om god værdiskabelse for aktionærerne, kan man med fordel st..
14
17 Jan
ZEAL
http://mediaroom.sanofi.com/suliquatm-approved-in-the-european-union-for-the-treatment-of-adults-wit..
14
17 Jan
FING-B
EBM inleder förundersökning i handeln med Fingerprint Realtid.se kan avslöja att Ekobrottsmyndighe..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - London Stock Exchange Group Plc

23/01/2017 10:32:57
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY ..

Alliance Trust PLC : Transaction in Own Shares

23/01/2017 07:00:01
23 January 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 20 January 2017 the Comp..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Fingerprint Cards' member of the board Lars Söderfjell taken into custody
2
Hands-on Techniques Provide Pain Relief at Faith Chiropractic, PS in Washington
3
Wichita Optometry Helps Dry Eye Sufferers with Cutting-Edge LipiFlow® Gland Function Treatment
4
Philips Lighting proposes two new Supervisory Board members
5
Atlantic Petroleum completes the sale of its Norwegian activities.

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 January 2017 14:44:20
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170120.2 - EUROWEB6 - 2017-01-23 15:44:20 - 2017-01-23 14:44:20 - 1000 - Website: OKAY